Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
10.99
+0.48 (4.57%)
Aug 12, 2025, 11:37 AM - Market open
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Paul A. Wagner |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G2084 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | SCHEDULE 13G/A | Filing |
| Aug 4, 2025 | SCHEDULE 13G/A | Filing |
| Jul 8, 2025 | SCHEDULE 13G | Filing |
| Jun 25, 2025 | 424B5 | Filing |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 424B5 | Filing |
| Jun 23, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |